

Ulcerative Colitis

**A study in the use of etrolizumab in patients with ulcerative colitis
(Eucalyptus)**

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Trial Status Completed	Trial Runs In 11 Countries	Trial Identifier NCT01336465 GP27778 ABS4986g
----------------------------------	--------------------------------------	--

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase II study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis.

Genentech, Inc. Sponsor	Phase 2 Phase
-----------------------------------	-------------------------

NCT01336465 GP27778 ABS4986g
Trial Identifiers

Eligibility Criteria:

Gender All	Age >=18 Years & <= 75 Years	Healthy Volunteers No
----------------------	--	---------------------------------
